{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":23,"n_cols":5,"rows_kept":23,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[17,2,17,3],[18,2,18,3],[20,2,20,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910298399603321"]
[null,null,"Titolo",null,"Drug Resistance in Leishmania Parasites : Consequences, Molecular Mechanisms and Possible Treatments / / edited by Alicia Ponte-Sucre, Maritza Padrón-Nieves"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer International Publishing : , : Imprint : Springer, , 2018"]
[null,null,"ISBN",null,"3-319-74186-1"]
[null,null,"Edizione",null,"[2nd ed. 2018.]"]
[null,null,"Descrizione fisica",null,"1 online resource (380 pages)"]
[null,null,"Disciplina",null,"616.9364"]
[null,null,"Soggetti",null,"Drug resistance"]
[{"$nulls":4},"Infectious diseases"]
[{"$nulls":4},"Pharmaceutical technology"]
[{"$nulls":4},"Vaccines"]
[{"$nulls":4},"Parasitology"]
[{"$nulls":4},"Microbiology"]
[{"$nulls":4},"Drug Resistance"]
[{"$nulls":4},"Infectious Diseases"]
[{"$nulls":4},"Pharmaceutical Sciences/Technology"]
[{"$nulls":4},"Vaccine"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Prologue -- Introduction -- Part I Determinant features in Leishmaniasis -- Molecular evolution and phylogeny of Leishmania -- The role of reservoirs: canine Leishmaniasis -- Epidemiology of Leishmaniasis in the time of drug resistance -- The role of the immune system in resistance to infection -- Part II Challenges in the diagnosis, treatment and control of Leishmaniasis in the times of drug resistance -- Co-infection with HIV -- Visceral Leishmaniasis -- Tegumentary Leishmaniasis -- Antimony accounted sequel post Kala-Azar dermal Leishmaniasis -- Part III Molecular featrues of drug resistant Leishmania -- Genetic Expression and drug resistance, the role of proteomics -- The role of AMC transporters in drug-resistant Leishmania -- Functional analysis of Leishmania membrane (non AMC) transporters involved in drug resistance -- Part IV Pharmacology and chemotherapy of Leishmaniasis -- Classical vs. novel treatment regimens -- Bioinformatics in Leishmania drug design -- Leishmanis "]
[{"$nulls":4},"mitochondria, a druggable organelle -- P-glycoprotein-like transporters in Leishmania: a search for reversal agents -- Part V Strategies to circumvent drug resistance in Leishmania -- The relevance of susceptibility tests, breakpoints and markers -- The concept of fitness in Leishmania."]
[null,null,null,"Sommario/riassunto","Drug resistance is a fundamental factor in treatment failure in diseases like leishmaniasis, although additional factors also play a role in this phenomenon. This volume is the second edition of a well-received book that provides a comprehensive update on the pathology of the disease, as well as on the concept of parasitic drug resistance, its molecular basis, consequences and possible treatments. A valuable resource for scientists both from academia and industry involved in biomedical research and drug design, the book provides the knowledge needed to understand leishmaniasis and to contibute to combatting this disease worldwide."]